Development of Emerin mRNA Lipid Nanoparticles to Rescue Myogenic Differentiation

Area of Science:

• Biochemistry
• Molecular Biology
• Genetic Medicine

Background:

• Emery-Dreifuss muscular dystrophy 1 (EDMD1) is caused by mutations in the EMD gene, leading to a lack of functional emerin protein.
• Current treatments for EDMD1 focus on symptom management, highlighting the need for therapies that address the root cause by restoring emerin.
• Emerin protein delivery via mRNA presents a potential therapeutic strategy to restore tissue homeostasis in EDMD1 patients.

Purpose of the Study:

• To evaluate the efficacy of lipid nanoparticles (LNPs) as a delivery system for emerin mRNA in treating EDMD1.
• To assess the restoration of emerin protein expression and its functional impact on myogenic progenitors.
• To determine the safety profile of emerin mRNA-loaded LNPs (EMD-LNPs).

Main Methods:

• Treatment of emerin-null myogenic progenitors with LNPs encapsulating emerin mRNA.
• Assessment of emerin protein expression levels and duration post-treatment.
• Evaluation of myogenic differentiation capacity in treated cells.
• Toxicity profiling of EMD-LNP administration.

Main Results:

• EMD-LNPs induced robust and sustained emerin protein expression in emerin-null cells for at least 4 days.
• Treatment with EMD-LNPs significantly enhanced the differentiation of myogenic progenitors.
• Toxicity assessment revealed minimal adverse effects at therapeutically effective doses of EMD-LNPs.

Conclusions:

• Lipid nanoparticles are a promising vehicle for delivering emerin mRNA to restore protein expression in EDMD1.
• EMD-LNP treatment demonstrates therapeutic potential by improving muscle cell differentiation and showing a favorable safety profile.
• This study validates EMD-LNPs as a viable therapeutic option and a tool for further EDMD pathology research.